Enrollment Completed in Ph 3 Bridging Study of Uproleselan in Chinese Patients with R/R AML January 10, 2024
Ph 1b portion of Ph 1b/2 lanraplenib study in patients with R/R FLT3-mutated AML completed January 10, 2024
Scemblix Shows Superior MMR Rates Vs. SoC TKIs In Ph 3 Trial For Newly Diagnosed Patients With CML January 10, 2024
FDA Clears IND Application for SENTI-202 for the Treatment of R/R Hematologic Malignancies Including AML January 4, 2024
Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb December 11, 2023
Encouraging Initial Data from Randomized SELECT-AML-1 Ph 2 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine Announced December 11, 2023
US FDA Accepts for Priority Review Application for Breyanzi (lisocabtagene maraleucel) for R/R CLL/SLL December 4, 2023
Supplemental BLA submitted to US FDA for obecabtagene autoleucel (obe-cel) for Patients with R/R Adult B-Cell ALL December 4, 2023
Successful Completion of Safety Cohort and Positive DSMB Results from TCB008’s Trial in AML Patients Announced November 15, 2023
Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Ph 3 Study of Lisaftoclax + Acalabrutinib in 1L CLL/SLL Patients October 25, 2023
First Patient Dosed in the Registrational Ph 3 Study of Olverembatinib in 1L Ph+ ALL Patients October 25, 2023
BRUKINSA Receives Positive Recommendation from NICE in U.K. for Adult Patients with CLL October 25, 2023
Global Registrational Ph 3 Study of Lisaftoclax in 1L CLL/SLL Patients Approved by the China CDE October 25, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
